Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-P2 alpelisib in PIK3CA-related overgrowth spectrum
2023-508530-34-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in PIK3CA-related overgrowth spectrum (PROS) comparing Alpelisib with Placebo (2 arms). Primary endpoint: Response by MRI lesion volume reduction. Planned start Apr 2021; status: authorised.
02
Drugs
alpelisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on 2023-508530-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508530-34-00.